Discover trends, market shifts, and competitive outlooks for the non-proliferative diabetic retinopathy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Projections for the CAGR of the Non-Proliferative Diabetic Retinopathy Market Size From 2025 to 2034?

The market size for non-proliferative diabetic retinopathy has been on a steady growth trajectory in the past years. The market is projected to escalate from $2.62 billion in 2024 to $2.84 billion in 2025, rising at a compound annual growth rate (CAGR) of 8.4%. The spike during the historical timeframe can be ascribed to factors such as the increasing incidence of diabetes, an aging demographic, heightened awareness, advancements in research, lifestyle modifications, and enhanced management of diabetes.

In the coming years, the non-proliferative diabetic retinopathy market size is anticipated to witness significant growth, projected to reach $3.87 billion in 2029 with a compound annual growth rate (CAGR) of 8.0%. This expected rise during the forecast period can be attributed to several factors such as the implementation of telemedicine, development of novel therapeutic measures, application of artificial intelligence, increased research and development investment, and the broadening of healthcare infrastructure. Key trends that are projected to shape the market in the forecast period are the growing use of artificial intelligence for screening and diagnosis purposes, the increasing demand for telemedicine and remote monitoring solutions, the advent of personalized medicine for diabetic retinopathy treatment, the heightened emphasis on preventive strategies and early intervention, and the increasing importance of patient-centered care models in managing diabetic retinopathy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp

Which Primay Drivers Are Accelerating Growth in the Non-Proliferative Diabetic Retinopathy Market?

An escalation in the cases of diabetes is anticipated to stimulate the expansion of the non-proliferative diabetic retinopathy market. Diabetes, a persistent metabolic disease, is typified by high blood sugar levels due to the pancreas failing to produce sufficient insulin, or the body’s cellular resistance to insulin effects. Inactive lifestyles, improper dietary habits, and inherited factors are key contributors to diabetes. It causes non-proliferative diabetic retinopathy by damaging retinal blood vessels, mainly from long-term exposure to heightened glucose levels in the blood, causing vision deterioration and potential loss of sight. For example, in June 2024, The National Health Service, a UK government department, reported that in 2023, the NHS identified an additional 549,000 individuals in England with potential risk for developing type 2 diabetes. This pushed the total count of non-diabetic hyperglycemia or pre-diabetes diagnosed with GP to 3,615,330. Compared to 3,065,825 in 2022, this is a significant increase of nearly 20%. Thus, the increasing cases of diabetes are fueling the growth of the non-proliferative diabetic retinopathy market.

How Is the Non-Proliferative Diabetic Retinopathy Market Segmented?

The non-proliferative diabetic retinopathy market covered in this report is segmented –

1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy

2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)

2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)

3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation

4) By Vitrectomy: Pars Plana Vitrectomy (Ppv), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15620&type=smp

Which Regions Are Key Players in the Growth of the Non-Proliferative Diabetic Retinopathy Market?

North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Non-Proliferative Diabetic Retinopathy Industry Dynamics?

Companies significant in the non-proliferative diabetic retinopathy market are utilizing AI-based cameras to enhance patient results and push forward progress in ophthalmic imaging. These AI-enabled cameras are devices armed with AI systems that contribute to the capture, analysis, and interpretation of eye images for both diagnostic and therapeutic strategies. For instance, Optomed, a medical technology company originating from Finland, introduced the Optomed Aurora AEYE, a handheld AI fundus camera in May 2024. This device, cutting-edge in its design, merges the handheld camera’s convenience with the power of artificial intelligence to deliver superior quality retinal images for the prompt detection and supervision of multiple eye ailments. The Optomed Aurora AEYE offers assistance in analyzing retinal images with AI algorithms to medical professionals. This technology ensures the fast and precise diagnosis of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

View the full report here:

https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

How Is the Non-Proliferative Diabetic Retinopathy Market Defined and What Are Its Core Parameters?

Non-proliferative diabetic retinopathy (NPDR) is a common complication of diabetes mellitus that affects the retina, the light-sensitive tissue lining the back of the eye. NPDR is characterized by changes in the blood vessels of the retina due to prolonged exposure to high levels of blood sugar (hyperglycemia) associated with diabetes. It is managed through a combination of medical interventions, lifestyle modifications, and regular eye examinations to prevent disease progression and preserve vision.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15620

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model